Verteporfin ameliorates fibrotic aspects of Dupuytren’s disease nodular fibroblasts irrespective the activation state of the cells
admin
Shih, B. & Bayat, A. Scientific understanding and clinical management of Dupuytren disease. Nat. Rev. Rheumatol. 6(12), 715–726 (2010).
Karkampouna, S. et al. Novel ex vivo culture method for the study of Dupuytren’s disease: Effects of TGFβ type 1 receptor modulation by antisense oligonucleotides. Mol. Ther. Nucl. Acids. 3, e142 (2014).
Larsen, S. et al. Genetic and environmental influences in Dupuytren’s disease: A study of 30,330 Danish twin pairs. J. Hand. Surg. 40(2), 171–176 (2015).
Dolmans, G. H. et al. Wnt signaling and Dupuytren’s disease. N. Engl. J. Med. 365(4), 307–317 (2011).
Becker, K. et al. Meta-analysis of genome-wide association studies and network analysis-based integration with gene expression data identify new suggestive loci and unravel a Wnt-centric network associated with Dupuytren’s disease. PLoS ONE 11(7), e0158101 (2016).
Ng, M. et al. A genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis. Am. J. Hum. Genet. 101(3), 417–427 (2017).
Sayadi, L. R. et al. The molecular pathogenesis of Dupuytren disease: Review of the literature and suggested new approaches to treatment. Annals Plast. Surg. 83(5), 594–600 (2019).
Pratt A, Ball C. Dupuytren ’ s disease—The role of hand therapy. In: Living Textbook of Hand Surgery 2015:1–7.
Ball, C., Izadi, D., Verjee, L. S., Chan, J. & Nanchahal, J. Systematic review of non-surgical treatments for early Dupuytren’s disease. BMC Musculoskelet. Disord. 17(1), 345 (2016).
Badalamente, M. A., Hurst, L. C. & Hentz, V. R. Collagen as a clinical target: Nonoperative treatment of Dupuytren’s disease. J. Hand. Surg. Am. 27(5), 788–798 (2002).
Hurst, L. C. et al. Injectable collagenase Clostridium histolyticum for Dupuytren’s ontracture. N. Engl. J. Med. 361(10), 968–979 (2009).
Scherman, P., Jenmalm, P. & Dahlin, L. B. Three-year recurrence of Dupuytren’s contracture after needle fasciotomy and collagenase injection: a two-centre randomized controlled trial. J. Hand. Surg. 43(8), 836–840 (2018).
Black, E. M. & Blazar, P. E. Dupuytren disease: An evolving understanding of an age-old disease. Am. Acad. Orthop. Surg. 19(12), 746–757 (2011).
Rodrigues, J. N. et al. Surgery for Dupuytren’s contracture of the fingers. Cochrane Database Syst. Rev. 12, CD010143 (2015).
Karkampouna, S. et al. Connective tissue degeneration: Mechanisms of palmar fascia degeneration (Dupuytren’s disease). Curr. Mol. Biol. Rep. 2(3), 133–140 (2016).
Karakaplan, M. Percutaneous needle aponeurotomy for the treatment of Dupuytren’s contracture. Jt. Dis. Relat. Surg. 30(1), 53–60 (2019).
Alfonso-Rodríguez, C. A. et al. Identification of histological patterns in clinically affected and unaffected palm regions in Dupuytren’s disease. PLoS ONE 9(11), e112457 (2014).
Szeto, S. G. et al. YAP/TAZ are mechanoregulators of TGF-β-Smad signaling and renal fibrogenesis. J. Am. Soc. Nephrol. 27(10), 3117–3128 (2016).
Carthy, J. M. TGFβ signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders. J. Cell. Physiol. 233(1), 98–106 (2018).
Vallée, A. & Lecarpentier, Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 9(1), 98 (2019).
Distler, J. H. W. et al. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 15(12), 705–730 (2019).
Krause, C., Kloen, P. & ten Dijke, P. Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren’s disease fibroblasts. Fibrogenesis Tissue Repair. 4(1), 14 (2011).
Badalamente, M. A., Sampson, S. P., Hurst, L. C., Dowd, A. & Miyasaka, K. The role of transforming growth factor beta in Dupuytren’s disease. J. Hand. Surg. Am. 21(2), 210–215 (1996).
Satish, L., Gallo, P. H., Baratz, M. E., Johnson, S. & Kathju, S. Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren’s – derived fibroblasts. BMC Musculoskelet. Disord. 12(1), 113 (2011).
Piersma, B., Bank, R. A. & Boersema, M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front. Med. 2, 1–14 (2015).
Piersma, B. et al. YAP1 is a driver of myofibroblast differentiation in normal and diseased fibroblasts. Am. J. Pathol. 185(12), 3326–3337 (2015).
Qin, Z., Xia, W., Fisher, G. J., Voorhees, J. J. & Quan, T. YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts. Cell Commun. Signal. 16(1), 18 (2018).
Lee, M. J., Byun, M. R., Furutani-Seiki, M., Hong, J. H. & Jung, H. S. YAP and TAZ regulate skin wound healing. J. Invest. Dermatol. 134(2), 518–525 (2014).
Mannaerts, I. et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol. 63(3), 679–688 (2015).
Liang, M. et al. Yap/Taz deletion in gli+ cell-derived myofibroblasts attenuates fibrosis. J. Am. Soc. Nephrol. 28(11), 3278–3290 (2017).
Zhang, W. & Kong, Y. YAP is essential for TGF-β-induced retinal fibrosis in diabetic rats via promoting the fibrogenic activity of Müller cells. J. Cell Mol. Med. 24(21), 12390–12400 (2020).
Leung, J. Y. et al. Sav1 loss induces senescence and Stat3 activation coinciding with tubulointerstitial fibrosis. Mol. Cell. Biol. 37(12), 1–17 (2017).
Du, K. et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology 154(5), 1465–1479 (2018).
Yu, H. et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. Mol. Immunol. 107, 29–40 (2019).
Jin, J. et al. Inhibition of yes-associated protein by verteporfin ameliorates unilateral ureteral obstruction-induced renal tubulointerstitial inflammation and fibrosis. Int. J. Mol. Sci. 21(21), 8184 (2020).
Francisco, J. et al. Blockade of fibroblast YAP attenuates cardiac fibrosis and dysfunction through MRTF-A inhibition. JACC Basic Transl. Sci. 5(9), 931–945 (2020).
Mohede, D. C. J., de Jong, I. J., Bank, R. A. & van Driel, M. F. Verteporfin as a medical treatment in Peyronie’s disease. Sex Med. 6(4), 302–308 (2018).
Futakuchi, A. et al. YAP/TAZ are essential for TGF-β2–mediated conjunctival fibrosis. Investig. Opthalmol. Vis. Sci. 59(7), 3069 (2018).
Shi-wen, X. et al. Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. J. Cell Commun. Signal 15(1), 71–80 (2021).
Gui, Y. et al. Yap/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis. J. Biol. Chem. 293(42), 16364–16375 (2018).
Kim, K. K., Sheppard, D. & Chapman, H. A. TGF-β1 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10(4), a022293 (2018).
Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J. Cell Physiol. 227(2), 493–507 (2012).
Gjaltema, R. A. F. & Bank, R. A. Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease. Crit. Rev. Biochem. Mol. Biol. 52(1), 74–95 (2017).
Karsdal, M. A. et al. The good and the bad collagens of fibrosis—Their role in signaling and organ function. Adv. Drug Deliv. Rev. 121, 43–56 (2017).
Fearing, B. V. et al. Verteporfin treatment controls morphology, phenotype, and global gene expression for cells of the human nucleus pulposus. JOR Spine. 3(4), 1–16 (2020).
Kim, C.-L., Choi, S.-H. & Mo, J.-S. Role of the Hippo pathway in fibrosis and cancer. Cells 8(5), 468 (2019).
Noguchi, S., Saito, A. & Nagase, T. YAP/TAZ signaling as a molecular link between fibrosis and cancer. Int. J. Mol. Sci. 19(11), 3674 (2018).
Hinz, B., McCulloch, C. A. & Coelho, N. M. Mechanical regulation of myofibroblast phenoconversion and collagen contraction. Exp. Cell Res. 379(1), 119–128 (2019).
ten Dam, E.-J.P.M., van Beuge, M. M., Bank, R. A. & Werker, P. M. N. Further evidence of the involvement of the Wnt signaling pathway in Dupuytren’s disease. J. Cell Commun. Signal 10(1), 33–40 (2016).
Marcos Ribes, B. et al. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. Eur. J. Hosp. Pharm. 27(6), 350–354 (2020).
Li, X., Zhu, L., Wang, B., Yuan, M. & Zhu, R. Drugs and targets in fibrosis. Front. Pharmacol. 8, 855 (2017).
Raghu, G. & Selman, M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am. J. Respir. Crit. Care Med. 191(3), 252–4 (2015).
Hughes, G., Toellner, H., Morris, H., Leonard, C. & Chaudhuri, N. Real world experiences: Pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J. Clin. Med. 5(9), 78 (2016).
Bando, M. et al. Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med. 55(5), 443–448 (2016).
